Open study on the antidiarrhoeal effectiveness of the L 105 compound.
The therapeutical effectiveness of L 105, a new drug preparation exhibiting antidiarrhoeal activity and containing Rifaxidin, was tested on 22 patients with acute gastroenteric syndrome of bacterial aetiology. In all patients there was a prompt restoration of intestinal function by the 2nd treatment day. Both local and systemic drug tolerance proved to be good in all cases.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000930:Antidiarrheals / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D002648:Child; D005243:Feces / Q000382:microbiology; D005260:Female; D005759:Gastroenteritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
D000930:Antidiarrheals; D012294:Rifamycins; D000078262:Rifaximin